Supernus Pharmaceuticals SUPN Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Supernus Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's net debt / EBITDA?
- Supernus Pharmaceuticals (SUPN) reported net debt / EBITDA of -3.9× in Q1 2026.
- How has Supernus Pharmaceuticals's net debt / EBITDA changed year-over-year?
- Supernus Pharmaceuticals's net debt / EBITDA decreased by 628.3% year-over-year, from -0.5× to -3.9×.
- What is the long-term trend for Supernus Pharmaceuticals's net debt / EBITDA?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's net debt / EBITDA has grown at a 20.6% compound annual growth rate (CAGR), from -1.2× to -3×.
- What does net debt / EBITDA mean?
- Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.